Atypical sorsby fundus dystrophy with a novel tyr159cys timp-3 mutation

Retinal Cases and Brief Reports

Volumn 7, Issue 1, 2013, Pages 71-74

  Fung, Adrian T ^a   Stöhr, Heidi ^b   Weber, Bernhard H F ^b   Holz, Frank G ^c   Yannuzzi, Lawrence A ^a  

^a VITREOUS RETINA MACULA CONSULTANTS OF NEW YORK   (United States)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c UNIVERSITY OF BONN   (Germany)

Author keywords

Sorsby fundus dystrophy; TIMP 3

Indexed keywords

BEVACIZUMAB; CYSTEINE; INDOCYANINE GREEN; TYROSINE;

ADULT; ARTICLE; ATYPICAL SORSBY FUNDUS DYSTROPHY; AUTOSOMAL DOMINANT INHERITANCE; CASE REPORT; CONSERVATIVE TREATMENT; EYE DISEASE; EYE EXAMINATION; FAMILY HISTORY; FLUORESCENCE ANGIOGRAPHY; GENE; GENETIC ASSOCIATION; HUMAN; INDOCYANINE GREEN ANGIOGRAPHY; MALE; MUTATIONAL ANALYSIS; PHOTODYNAMIC THERAPY; POINT MUTATION; RECURRENT DISEASE; RETINA DETACHMENT; RETINA MACULA HEMORRHAGE; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; SUBRETINAL FLUID; SUBRETINAL NEOVASCULARIZATION; TIMP 3 GENE; VISUAL ACUITY; VISUAL IMPAIRMENT;

EID: 84878029943     PISSN: 19351089     EISSN: 19371578     Source Type: Journal    
DOI: 10.1097/ICB.0b013e318267101e     Document Type: Article

References (18)

1. Weber BH, Vogt G, Pruett RC, et al. Mutations in the tissue inhibitor of metalloproteinases-3 (TIMP3) in patients with Sorsby's fundus dystrophy. Nat Genet 1994;8:352-356. (Pubitemid 24375600)
2. Atan D, Gregory Evans CY, Louis D, Downes SM. Sorsby fundus dystrophy presenting with choroidal neovascularisation showing good response to steroid treatment. Br J Ophthalmol 2004;88:440-441. (Pubitemid 38333732)
3. Sivaprasad S, Webster AR, Egan CA, et al. Clinical course and treatment outcomes of Sorsby fundus dystrophy. Am J Ophthalmol 2008;146:228-234.
4. Assink JJ, de Backer E, ten Brink JB, et al. Sorsby fundus dystrophy without a mutation in the TIMP-3 gene. Br J Ophthalmol 2000;84:682-686. (Pubitemid 30438540)
5. Peters AL, Young MJ, Miller JK. Optical coherence tomography for assessing disease progression in sorsby fundus dystrophy. Retina 2006;26:1082-1084. (Pubitemid 44973234)
6. Felbor U, Benkwitz C, Klein ML, et al. Sorsby fundus dystrophy: Reevaluation of variable expressivity in patients carrying a TIMP3 founder mutation. Arch Ophthalmol 1997;115:1569-1571. (Pubitemid 28007140)
7. Saihan Z, Li Z, Rice J, et al. Clinical and biochemical effects of the E139K missense mutation in the TIMP3 gene, associated with Sorsby fundus dystrophy. Mol Vis 2009;15:1218-1230.
8. Weber BH, Vogt G, Wolz W, et al. Sorsby's fundus dystrophy is genetically linked to chromosome 22q13-qter. Nat Genet 1994; 7:158-161. (Pubitemid 24174654)
9. Fogarasi M, Janssen A, Weber BHF, Stohr H. Molecular dissection of TIMP3 mutation S156C associated with Sorsby fundus dystrophy. Matrix Biol 2008;27:381-392.
10. Felbor U, Suvanto EA, Forsius HR, et al. Autosomal recessive Sorsby fundus dystrophy revisited: Molecular evidence for dominant inheritance. Am J Hum Genet 1997;60:57-62. (Pubitemid 26427778)
11. Felbor U, Stohr H, Amann T, et al. A second independent Tyr168Cys mutation in the tissue inhibitor of metalloproteinases-3 (TIMP3) in Sorsby's fundus dystrophy. J Med Genet 1996;33:233-236. (Pubitemid 26070659)
12. Chong NHV, Kvanta A, Seregard S, et al. TIMP-3 mRNA is not overexpressed in Sorsby fundus dystrophy. Am J Ophthalmol 2003;136:954-955. (Pubitemid 37330058)
13. Barbazetto IA, Hayashi M, Klais CM, et al. A novel TIMP3 mutation associated with Sorsby fundus dystrophy. Arch Ophthalmol 2005;123:542-543. (Pubitemid 40489928)
14. Qi JH, Ebrahem Q, Moore N, et al. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): Inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med 2003;9:407-415. (Pubitemid 36460074)
15. Peiretti E, Klancnik JM Jr, Spaide RF, Yannuzzi L. Choroidal neovascularization in sorsby fundus dystrophy treated with photodynamic therapy and intravitreal triamcinolone acetonide. Retina 2005;25:377-379. (Pubitemid 40517374)
16. Gemenetzi MK, Luff AJ, Lotery AJ. Successful treatment of choroidal neovascularization secondary to sorsby fundus dystrophy with intravitreal bevacizumab. Retin Cases Brief Rep 2011;5:132-135.
17. Holz FG, Haimovici R, Wagner DG, Bird AC. Recurrent choroidal neovascularization after laser photocoagulation in Sorsby's fundus dystrophy. Retina 1994;14:329-334. (Pubitemid 24310150)
18. Weber BHF, Lin B, White K, et al. A mouse model for Sorsby fundus dystrophy. Invest Ophthalmol Vis Sci 2002;43: 2732-2740. (Pubitemid 34809467)